Startseite Kongressberichte & Archiv Prostate Cancer Oral Abstract & Rapid Abstract Session

Oral Abstract Session: Prostate Cancer

Session Link

 

 
Felix Y. Feng, Clemente Aguilar-Bonavides, et al.
 
The authors conclude: Although the data require confirmation in larger studies, these molecular determinants may have utility in selecting pts with nmCRPC who may derive the most benefit from APA and other androgen signaling inhibitors. Clinical trial information: NCT01946204
 
 
Dana E. Rathkopf, Eleni Efstathiou, Gerhardt Attard, et al.
 
The authors conclude: The ACIS final analysis met the primary end point and demonstrated a 31% reduction in risk of radiographic progression or death in chemo-naive mCRPC pts treated with the combination of APA + AAP with ADT vs AAP with ADT. Funding: Janssen Research & Development. Trial registration: NCT02257736. Clinical trial information: NCT02257736
 
Pirus Ghadjar, Stefanie Hayoz, Juerg Bernhard, et al.
 
The authors conclude: Dose-intensified salvage RT to the prostate bed was not superior to conventional dose RT. However, dose-intensified salvage RT was associated with higher frequencies of late grade ≥ 2 gastrointestinal toxicity. Clinical trial information: NCT01272050
 
 
Jonathan D. Tward, Constantine Mantz, Neal D. Shore, et al.
 
The authors conclude: CCR is a highly precise and accurate predictor of metastasis in men undergoing dose-escalated RT, with or without ADT. CCR adds clinically actionable information relative to guideline recommended therapies that are based on NCCN risk groups or CAPRA alone. Men with scores below the multimodality threshold may not significantly reduce their 10-year risk of metastasis with the addition of ADT.
 

Rapid Abstract Session: Prostate Cancer

Session Link:

 
Kim N. Chi, Simon Chowdhury, Anders Bjartell, et al.
 
The authors conclude: With close to 4 yrs of follow-up, the final analysis of TITAN demonstrated that in a broad population of pts with mCSPC, APA plus ADT provides an improvement in OS with a 35% reduction in risk of death, which increased to 48% reduction after adjusting for pts who crossed over from PBO to APA. In addition, there was consistent benefit with APA in other end points, including delaying castration resistance, and HRQoL continued to be maintained with an acceptable safety profile. Clinical trial information: NCT02489318
 
 
Leonard J. Appleman, Michael P. Kolinsky, William R. Berry, et al.
 
The authors conclude: After another year of follow-up, pembro + docetaxel and prednisone showed improved ORR and PSA response rates compared to the prior dataset in pts with mCRPC previously treated with abi or enza. Safety was consistent with known profiles of each agent and will be further evaluated in a phase 3 study (KEYNOTE-921). Clinical trial information: NCT02861573
 
 
Karim Fizazi, Pablo González Mella, Daniel Castellano, et al.
 
The authors conclude: NIVO + DOCE has encouraging clinical activity in patients with chemotherapy-naïve mCRPC, regardless of prior NAT, with a safety profile consistent with those of the individual agents. These outcomes support the ongoing phase 3 CheckMate 7DX trial of NIVO + DOCE vs placebo + DOCE for mCRPC (NCT04100018). Clinical trial information: NCT03338790
 
 
Johann S. De Bono, Christopher Sweeney, Sergio Bracarda, et al.
 
The authors conclude: Analyses of more-stringent biomarkers associated with activation of the PI3K/AKT pathway further support ipat + abi as a treatment option for first-line mCRPC with PI3K/AKT pathway alterations, a mCRPC subtype with a worse prognosis. Clinical trial information: NCT03072238
 
 
Tamer Khashab, Alexander D. Le, Samantha Cohen, et al.
 
The authors conclude: The observed high frequency of mutations in key PC drivers in AA patients may reflect differences in disease biology between racial/ethnic groups or the more advanced disease presentation of AA patients due to socioeconomic factors delaying access to healthcare. Our study provides a real-world snapshot of the genomic landscape of advanced PC in a safety net hospital serving large racial/ethnic minority populations and highlights the role that NGS testing can play to improve their access to treatment with novel targeted therapies and to biomarker-based Precision Oncology clinical trials.
 
 
Todd M. Morgan, Linda A. Okoth, Daniel E. Spratt, et al.
 
The authors conclude: In the first ever randomized trial testing the impact of a prostate cancer genomic classifier on treatment decisions, the use of a GC post-RP impacted post-operative treatment in a manner concordant with classifier risk. Further follow-up will be necessary to assess the impact of GC testing on oncologic outcomes. Clinical trial information: NCT02783950